Results from Gene ID Studies Could Lead to New Dxs for Genomic Health

Jun 11, 2008

Premium

Oncotype DX maker Genomic Health announced last week that two studies recently presented at an international oncology conference could lead to the development of new predictive tests to help determine which patients are likely to respond to the targeted colon cancer drug Erbitux and the breast cancer chemotherapy Taxotere.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Yep, Couple of Concerns There

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

Passing on Trauma, Maybe

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.